The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Clinical analysis of anti-Ma2-associated encephalitis
Abstract
Increasing experience indicates that anti-Ma2-associated encephalitis differs from classical paraneoplastic limbic or brainstem encephalitis, and therefore may be unrecognized. To facilitate its diagnosis we report a comprehensive clinical analysis of 38 patients with anti-Ma2 encephalitis. Thirty-four (89%) patients presented with isolated or combined limbic, diencephalic or brainstem dysfunction, and four with other syndromes. Considering the clinical and MRI follow-up, 95% of the patients developed limbic, diencephalic or brainstem encephalopathy. Only 26% had classical limbic encephalitis. Excessive daytime sleepiness affected 32% of the patients, sometimes with narcolepsy-cataplexy and low CSF hypocretin. Additional hormonal or MRI abnormalities indicated diencephalic-hypothalamic involvement in 34% of the patients. Eye movement abnormalities were prominent in 92% of the patients with brainstem dysfunction, but those with additional limbic or diencephalic deficits were most affected; 60% of these patients had vertical gaze paresis that sometimes evolved to total external ophthalmoplegia. Three patients developed atypical parkinsonism, and two a severe hypokinetic syndrome with a tendency to eye closure and dramatic reduction of verbal output. Neurological symptoms preceded the tumour diagnosis in 62% of the patients. Brain MRI abnormalities were present in 74% of all patients and 89% of those with limbic or diencephalic dysfunction. Among the 34 patients with cancer, 53% had testicular germ-cell tumours. Two patients without evidence of cancer had testicular microcalcification and one cryptorchidism, risk factors for testicular germ-cell tumours. After neurological syndrome development, 17 of 33 patients received oncological treatment (nine also immunotherapy), 10 immunotherapy alone, and six no treatment. Overall, 33% of the patients had neurological improvement, three with complete recovery; 21% had long-term stabilization, and 46% deteriorated. Features significantly associated with improvement or stabilization included, male gender, age <45 years, testicular tumour with complete response to treatment, absence of anti-Ma1 antibodies and limited CNS involvement. Immunosuppression was not found to be associated with improvement but was clearly effective in some patients. Fifteen patients (10 women, five men) had additional antibodies to Ma1. These patients were more likely to have tumours other than testicular cancer and to develop ataxia, and had a worse prognosis than patients with only anti-Ma2 antibodies (two women, 21 men); 67% of deceased patients had anti-Ma1 antibodies. Anti-Ma2 encephalitis (with or without anti-Ma1 antibodies) should be suspected in patients with limbic, diencephalic or brainstem dysfunction, MRI abnormalities in these regions, and inflammatory changes in the CSF. In young male patients, the primary tumour is usually in the testis, in other patients the leading neoplasm is lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mignot, E., Lammers, G. J., Ripley, B., Okun, M., Nevsimalova, S., Overeem, S., Vankova, J., Black, J., Harsh, J., Bassetti, C., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1553 · Cited by 1,126
Gultekin, S. H. (2000) · Brain · doi:10.1093/brain/123.7.1481 · Cited by 1,123
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients
Graus, F. (2001) · Brain · doi:10.1093/brain/124.6.1138 · Cited by 897
Voltz, R., Gultekin, S. H., Rosenfeld, M. R., Gerstner, E., Eichen, J., Posner, J. B., & Dalmau, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906103402303 · Cited by 379
Self-citationNeurologic Complications of Cancer
Wen, P. Y., & Glantz, M. J. (2003) · Neurologic Clinics · doi:10.1016/s0733-8619(02)00100-7 · Cited by 361
Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies
Rojas-Marcos, I., Graus, F., Keime-Guibert, F., Reñé, R., Delattre, J., Ramon, J. M., Dalmau, J. O., & Posner, J. B. (2000) · Neurology · doi:10.1212/wnl.55.5.713 · Cited by 323
Self-citationMolecular and clinical diversity in paraneoplastic immunity to Ma proteins
Rosenfeld, M. R., Eichen, J. G., Wade, D. F., Posner, J. B., & Dalmau, J. (2001) · Annals of Neurology · doi:10.1002/ana.1288 · Cited by 291
Self-citationDalmau, J., Gultekin, S. H., Voltz, R., Hoard, R., DesChamps, T., Balmaceda, C., Batchelor, T., Gerstner, E., Eichen, J., Frennier, J., et al. (1999) · Brain · doi:10.1093/brain/122.1.27 · Cited by 236
Self-citationNeurologic Complications of Cancer
O'Neill, B. P. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.319-a · Cited by 166
Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis
Overeem, S., Dalmau, J. O., Bataller, L., Nishino, S., Mignot, E. J.-M., Verschuuren, J. J. G. M., & Lammers, G. J. (2004) · Neurology · doi:10.1212/01.wnl.0000101718.92619.67 · Cited by 141
Self-citationJansen, M., Perry, A., Heffner, R. R., & Louis, D. N. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0434-1.00069-4 · Cited by 133
Wyburn-Mason, R. (1969) · BMJ · doi:10.1136/bmj.3.5665.302-c · Cited by 126
Hierons, R., Janota, I., & Corsellis, J. (1978) · Psychological Medicine · doi:10.1017/s0033291700006607 · Cited by 88
Paraneoplastic brain stem encephalitis in a woman with anti-Ma2 antibody
Barnett, M. H. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.2.222 · Cited by 67
Neurologic paraneoplastic syndromes
Dropcho, E. J. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00296-7 · Cited by 63
Paraneoplastic limbic encephalopathy with testicular carcinoma: A reversible neurologic syndrome
Burton, G. V., Bullard, D. E., Walther, P. J., & Burger, P. C. (1988) · Cancer · Cited by 58
Landolfi, J. C., & Nadkarni, M. A. (2003) · Neuro-Oncology · doi:10.1215/s1152851702000467 · Cited by 56
Debourdeau, P., Gligorov, J., & Zammit, C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911043411916 · Cited by 22
Neurologic paraneoplastic syndromes
Dropcho, E. J. (2004) · Current Oncology Reports · doi:10.1007/s11912-996-0006-8 · Cited by 13
Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease.
van Geel (2001) · Open Repository and Bibliography (University of Luxembourg) · doi:10.1002/1531-8249(20010201)49:2 · Cited by 7
Hierons, R. (1996) · Neurocase · doi:10.1093/neucas/2.4.259-q · Cited by 4
Cited by
A clinical approach to diagnosis of autoimmune encephalitis
Graus, F., Titulaer, M. J., Balu, R., Benseler, S., Bien, C. G., Cellucci, T., Cortese, I., Dale, R. C., Gelfand, J. M., Geschwind, M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00401-9 · Cited by 4,516
Self-citationParaneoplastic anti– N ‐methyl‐ D ‐aspartate receptor encephalitis associated with ovarian teratoma
Dalmau, J., Tüzün, E., Wu, H., Masjuan, J., Rossi, J. E., Voloschin, A., Baehring, J. M., Shimazaki, H., Koide, R., King, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21050 · Cited by 2,492
Paraneoplastic Syndromes Involving the Nervous System
Darnell, R. B., & Posner, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023009 · Cited by 1,062
Paraneoplastic syndromes of the CNS
Dalmau, J., & Rosenfeld, M. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70060-7 · Cited by 873
Self-citationParaneoplastic Syndromes: An Approach to Diagnosis and Treatment
Pelosof, L. C., & Gerber, D. E. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0099 · Cited by 773
Metadata
- Authors
- Dalmau, J.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-06-16
- Volume
- 127
- Issue
- 8
- Pages
- 1831-1844
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W1986772640
- Cited by
- 771
- References
- 21
- FWCI
- 14.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.